Search results
Results from the WOW.Com Content Network
With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? ... The good news is that AbbVie has ...
And since it split from Abbott in 2013, AbbVie has raised its payout by 288%. The ability to maintain a solid dividend program for years is an incredibly attractive quality to long-term investors.
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development , over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
A splashy recent acquisition by the company might not be panning out.
The drugmaker has convincingly laid to rest the biggest threat to its top line.
For premium support please call: 800-290-4726 more ways to reach us